Home
About
Overview
Sharing Data
ORCID
Help
History (266)
Effect of Lumacaftor/Ivacaftor on Pulmonary Exacerbation Rates in Members with Cystic Fibrosis in a Medicaid Population.
Gene therapy for alpha-1 antitrypsin deficiency: an update.
From strength to precision: A systematic review exploring the clinical utility of 7-Tesla magnetic resonance imaging in abdominal imaging.
Axis, Cervical Vertebra
N-acetylcysteine for idiopathic pulmonary fibrosis: the door is still open.
See All 266 Pages
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
N-acetylcysteine for idiopathic pulmonary fibrosis: the door is still open.
Raghu G, Noth I, Martinez F. N-acetylcysteine for idiopathic pulmonary fibrosis: the door is still open. Lancet Respir Med. 2017 01; 5(1):e1-e2.
View in:
PubMed
subject areas
Acetylcysteine
Administration, Inhalation
Humans
Idiopathic Pulmonary Fibrosis
Pulmonary Fibrosis
Vital Capacity
authors with profiles
Fernando J Martinez MD, MS